Slides and webcasts from ESMO Virtual Plenaries are open to all ESMO Account holders, according to the presenters' agreement to release them.
Login and Watch now!
KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC
- Start date
- 15 Jul 2021
- End date
- 16 Jul 2021
The ESMO Virtual Plenaries are freely available to all healthcare professionals working in Oncology.
Programme
Thursday, 15 July 2021
19:30-20:30 CEST
Welcome and introduction, Scientific background and context
Fabrice André, Gustave Roussy, Villejuif, France
KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC
Peter Schmid, Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University London, London, UK
Critical analysis and perspectives
Giuseppe Curigliano, IEO - European Institute of Oncology, Milan, Italy
Discussion and Q&A (i)
Faculty and online audience
Friday, 16 July 2021
13:15-14:25 CEST (07:15 EDT / 19:15 SGT / 20:15 KST / 21:15 AEST)
Virtual Plenary Expert Insights: Webcast of 15 July presentations, Discussion and Q&A (ii)
Faculty and online audience:
Chair: Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Australia
Peter Schmid, Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University London, London, UK
Giuseppe Curigliano, IEO - European Institute of Oncology, Milan, Italy
Lisa Carey, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA
Sung-Bae Kim, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
Yoon-Sim Yap, NCCS - National Cancer Centre Singapore
